Bio-Convert Develops QR-02, a Potential Breakthrough in the Treatment of Oral Leukoplakia 

Stock Information for Nordicus Partners Corp

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Nordicus Partners Corp

Bio-Convert Receives Positive Feedback from The Danish Medicine Agency (DKMA) on its Lead Drug Candidate, QR-02 for Oral Leukoplakia
Orocidin's QR-01 Shows Positive Results in Treating Periodontitis in Dogs
Orocidin and Syngene Partner to Accelerate Biotech Innovation
Orocidin QR-01 Shows a Good Safety Profile in Preclinical Toxicity Study
Oricidin Launches Groundbreaking Dental Gel for Long-Term Periodontitis Treatment
Nordicus Partners Corporation Announces Key Milestone in Development of Orocidin's Breakthrough Treatment for Periodontitis
Orocidin and Bio-Convert expects to begin pilot efficacy studies in 2025
NORDICUS now trading under symbol NORD

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.